Enterprise record

ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:29100043-d006-4164-b99a-e78fd7d5dfabVersion: public-1As of: unavailable

21 published Claims2 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 30, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 29, 2026

    Supports 5 claims
    • Legal Name: ARS Pharmaceuticals, Inc. · Claim reviewed: Sep 29, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 29, 2026
    • Published Fact: US · Claim reviewed: Sep 29, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 29, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 29, 2026

  2. DEF 14A spry-20260429.htm

    sec proxy · Source published: Apr 29, 2026 · Retrieved: Sep 2, 2026

    Supports 16 claims
    • Leadership Role: Brenton L. Saunders: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Laura Shawver: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Michael Kelly: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Peter A Thompson: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Peter Kolchinsky: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Phillip Schneider: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Pratik Shah: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Rajeev Dadoo: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Saqib Islam: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Alexander A. Fitzpatrick: Chief Legal Officer and Secretary · Claim reviewed: Sep 29, 2026
    • Leadership Role: Brian Dorsey: Chief Operating Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Eric Karas: Chief Commercial Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Justin Chakma: Chief Business Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Kathleen D. Scott: Chief Financial Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Richard Lowenthal: President and Chief Executive Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Sarina Tanimoto: Chief Medical Officer · Claim reviewed: Sep 29, 2026